{"id":"m-cenk","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL286727","moleculeType":"Small molecule","molecularWeight":"106.17"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"M-CENK works by blocking the CD47/SIRPα axis, which is a checkpoint that cancer cells use to evade the immune system. By blocking this axis, M-CENK allows the immune system to recognize and attack cancer cells more effectively.","oneSentence":"M-CENK is a cancer immunotherapy that targets the CD47/SIRPα axis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:58:52.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic solid tumors"}]},"trialDetails":[{"nctId":"NCT04898543","phase":"PHASE1","title":"QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2021-06-21","conditions":"Metastatic Solid Tumor","enrollment":50},{"nctId":"NCT06710288","phase":"PHASE2","title":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2024-11-06","conditions":"Platinum-resistant Ovarian Cancer","enrollment":20},{"nctId":"NCT06765954","phase":"PHASE2","title":"Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-06-01","conditions":"High-risk Prostate Cancer","enrollment":20},{"nctId":"NCT06765902","phase":"PHASE2","title":"Immunotherapy Before and After Surgery","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-05-15","conditions":"High-risk Prostate Cancer","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Autologous Memory Cytokine Enriched Natural Killer"],"phase":"phase_2","status":"active","brandName":"M-CENK","genericName":"M-CENK","companyName":"ImmunityBio, Inc.","companyId":"immunitybio-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"M-CENK is a cancer immunotherapy that targets the CD47/SIRPα axis. Used for Metastatic solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}